Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report

[1]  V. Servois,et al.  Novel patterns of response under immunotherapy , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R. Motzer,et al.  Avelumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[3]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[4]  T. Powles,et al.  The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma , 2018, British Journal of Cancer.

[5]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[6]  T. Choueiri,et al.  Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. , 2015, European journal of cancer.

[7]  Dae-Ho Lee,et al.  Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor , 2015, Cancer Chemotherapy and Pharmacology.

[8]  R. Motzer,et al.  Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis , 2013, Journal of clinical pharmacology.

[9]  Y. Tomita,et al.  Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. , 2010, European urology.